T-Dxd Demonstrates High Levels Of Efficacy In Patients With Her2+ Unresectable And/Or Mbc Previo...

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previo...

DESTINY-Breast02: high levels of efficacy of T-DXd in previously treated HER2+ breast cancer

DESTINY-Breast04: T-DXd for patients with HER2-low mBC

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer

Highlights on T-DXd in pretreated HER2-expressing solid tumours : The DESTINY-PanTumor02 study

European Society for Medical Oncology (ESMO)

Treatment Updated for HER2 Positive Breast Cancer: Changing Paradigms

Total Health | Oncology

DESTINY-Breast04 Study Discussion - OncBrothers (Rohit and Rahul Gosain) with Dr. Shanu Modi

OncBrothers: Practice-Changing Cancer Discussions

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Updated analysis of DESTINY-Gastric02: T-DXd in HER2+ GEJ cancer who progressed with trastuzumab

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer

Dr Waks on Key Questions Regarding the First-Line Use of T-DXd in HER2+ Breast Cancer

Efficacy of trastuzumab deruxtecan in HER2-low metastatic breast cancer

DESTINY-Breast03: safety follow-up results

Trastuzumab deruxtecan shows benefit in patients with HER2 + mBC

DESTINY-Gastric02: 2L T-DXd in HER2+ gastric cancers

DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancer

Choosing between tucatinib and T-DXd in HER2+ breast cancer

HER2+ MBC | 2023 Best of Breast Conference

Total Health | Oncology